GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers

Wang, Jun; Xu, Wen; Wang, Beihe; Guo, Lin; Yu, Wei; Abudurexiti, Mierxiati; Zhu, Wenkai; Liu, Chang; Qin, Xiaojian; Dai, Bo; Wan, Fangning; Zhang, Ye; Zhu, Yao; Ye, Dingwei

doi:10.1016/j.canlet.2020.05.007

Cited by 48 publications

(42 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The metabolic role of IGF2BP2 in cancers is scarce. However, available evidence demonstrates that IGF2BP2 targets GLUT1, promoting aerobic glycolysis and proliferation of PDAC cells [68,[75][76][77]. IGF2BP2 also promotes metabolism of esophageal cancer and HNSCC [16,67].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers

2021

View full text Add to dashboard Cite

The human insulin-like growth factor 2 (IGF2) mRNA binding proteins 2 (IGF2BP2/IMP2) is an RNA-binding protein that regulates multiple biological processes. Previously, IGF2BP2 was thought to be a type 2 diabetes (T2D)-associated gene. Indeed IGF2BP2 modulates cellular metabolism in human metabolic diseases such as diabetes, obesity and fatty liver through post-transcriptional regulation of numerous genes in multiple cell types. Emerging evidence shows that IGF2BP2 is an N6-methyladenosine (m6A) reader that participates in the development and progression of cancers by communicating with different RNAs such as microRNAs (miRNAs), messenger RNAs (mRNAs) and long non-coding RNAs (lncRNAs). Additionally, IGF2BP2 is an independent prognostic factor for multiple cancer types. In this review, we summarize the current knowledge on IGF2BP2 with regard to diverse human metabolic diseases and its potential for cancer prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…IGF2BP2 is also over-expressed in PDAC [68,69]. Meanwhile, Glucose transporter 1 (GLUT1) is an integral membrane protein consisting of 12 transmembrane helices and an intracellular domain which promotes aerobic glycolysis and proliferation of cancer cells [75][76][77].…”

Section: Igf2bp2 In Pancreatic Cancermentioning

confidence: 99%

The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers

2021

View full text Add to dashboard Cite

show abstract

“…FKBP52, a large peptidylproyl cis-trans isomerase immunophilin protein; GC, glucocorticoid; KLF9, Kruppel-like factor 9; p23, the small, acidic co-chaperone; PI3K/AKT, PI3K/PKB; PSA, prostate-specific antigen prostate cancer cells. GLUT1 is a GLUT (Class 1 transporters) family member and is associated with poor prognosis (Wang, Xu, et al, 2020). The GLUT1 gene promoter directly binds to androgen receptor, which promotes GLUT1 transcription.…”

Section: Glycolysismentioning

confidence: 99%

“…Glucose transporters (GLUTs) are up‐regulated in prostate cancer cells. GLUT1 is a GLUT (Class 1 transporters) family member and is associated with poor prognosis (Wang, Xu, et al, 2020). The GLUT1 gene promoter directly binds to androgen receptor, which promotes GLUT1 transcription.…”

Section: Mechanisms Of Enzaluide Resistance In Castration‐resistant Pmentioning

confidence: 99%

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

Wang

Chen

et al. 2020

British J Pharmacology

View full text Add to dashboard Cite

Prostate cancer is the second most common malignancy in men and androgen deprivation therapy is the first-line therapy. However, most cases will eventually develop castration-resistant prostate cancer after androgen deprivation therapy treatment. Enzalutamide is a second-generation androgen receptor antagonist approved by the Food and Drug Administration to treat patients with castrationresistant prostate cancer. Unfortunately, patients receiving enzalutamide treatment will ultimately develop resistance via various complicated mechanisms. This review examines the emerging information on these resistance mechanisms, including androgen receptor-related signalling pathways, glucocorticoid receptor-related pathways and metabolic effects. Notably, lineage plasticity and phenotype switching, gene polymorphisms and the relationship between microRNAs and drug resistance are addressed. Furthermore, potential therapeutic strategies for enzalutamideresistant castration-resistant prostate cancer treatment are suggested, which can help discover more effective and specific regimens to overcome enzalutamide resistance.

show abstract

“…hepatocellular carcinoma, renal cell carcinoma and gastric cancer). [8][9][10][11] Previous studies have revealed that the rate of glucose metabolism in cancer cells is associated with the expression level of GLUT1. 12 Recently, Ning Yan et al reported the crystal structure of human GLUT1, which had led to the development of small molecule GLUT1 inhibitors for cancer therapeutics.…”

Section: Introductionmentioning

confidence: 99%

“Sweet tooth”-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy

Ding

Zheng

et al. 2021

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers

Cited by 48 publications

References 41 publications

The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers

The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers

Mechanisms of enzalutamide resistance in castration‐resistant prostate cancer and therapeutic strategies to overcome it

“Sweet tooth”-oriented SN38 prodrug delivery nanoplatform for targeted gastric cancer therapy

Contact Info

Product

Resources

About